Načítá se...
Phase III trial (EORTC 10994/BIG 1-00) assessing the value of p53 using a functional assay to predict sensitivity to a taxane versus non taxane primary chemotherapy in breast cancer: final analysis
BACKGROUND: This study tested the hypothesis that docetaxel confers a greater advantage over anthracyclines in p53 mutant compared to p53 wild type breast cancers. METHODS: Patients with locally advanced, inflammatory or large operable breast cancers were randomised to receive neoadjuvant chemothera...
Uloženo v:
| Hlavní autoři: | , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
2011
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4172919/ https://ncbi.nlm.nih.gov/pubmed/21570352 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S1470-2045(11)70094-8 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|